Search | Clinical Trials Finder

Conditions: Sphingolipidoses, Enzyme Deficiency
Interventions: no intervention; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nephrotic Syndrome
Interventions: Implementation of a gluten-free diet; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 9 Months to 18 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions: Atacicept; Drug
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Idiopathic Nephrotic Syndrome
Interventions: Standard of Care, UrApp; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon

Conditions: Diabetic Nephropathy, Nephrotic Syndrome
Interventions: ACTH; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Interventions: Sirolimus; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 13 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nephrotic Syndrome
Interventions: ADX-629; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 11
States / cities: Northridge, California • Aurora, Colorado • Lauderdale Lakes, Florida + 8 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: RE-021 (Sparsentan), Irbesartan; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 8 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 28
States / cities: San Diego, California • Torrance, California • Denver, Colorado + 19 more

Conditions: Chronic Kidney Disease, Glomerulopathy
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2030
U.S. locations: 5
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Charlotte, North Carolina + 1 more

Conditions: Crohn's Disease, Nephrotic Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 5 Years to 21 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions: Interview; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Nephrotic Syndrome, Proteinuria
Interventions: apixaban; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 79 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Nephrosis, Focal Lipoid Glomerulosclerosis
Interventions: Oral dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Nephrotic Syndrome, Frequently Relapsing Nephrotic Syndrome
Interventions: Transcutaneous Auricular Vagus Nerve (taVNS) stimulation; Device
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Interventions: D-Galactose; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Nephrotic Syndrome, Membranous Nephropathy
Interventions: Apixaban 5 MG; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions: Sparsentan; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more

Conditions: Healthy Volunteers
Interventions: GFB-887, Placebo; Drug
Lead sponsor: Goldfinch Bio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Proteinuria, Kidney Injury, Chronic Kidney Disease
Interventions: Not listed
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years to 90 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Focal Segmental Glomerulosclerosis
Interventions: CXA-10; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Frequent Relapsing Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome
Interventions: Rituximab, MMF; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Glomerular Disease
Interventions: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks; Dietary Supplement
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more

Conditions: Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions: WAL0921, Placebo; Drug
Lead sponsor: Walden Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more

Search by objective public record fields.

SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International)

Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker

Atacicept in Multiple Glomerular Diseases

UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center

Glucocorticoid-induced Osteopenia in Children

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

Pharmacokinetics of Apixaban in Nephrotic Syndrome

Steroid Treatment for Kidney Disease

Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome

Vitamin D Supplementation in Glomerular Disease

Study of WAL0921 in Patients With Glomerular Kidney Diseases